Literature DB >> 21761590

Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic.

Joseph T Wu1, Cheuk Kwong Lee, Benjamin J Cowling, Kwok Yung Yuen.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21761590      PMCID： PMC3357494     

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN： 1750-2640            Impact factor:   4.380


× No keyword cloud information.
  11 in total

1.  Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Authors:  Thomas C Luke; Edward M Kilbane; Jeffrey L Jackson; Stephen L Hoffman
Journal:  Ann Intern Med       Date:  2006-08-29       Impact factor: 25.391

2.  Treatment with convalescent plasma for influenza A (H5N1) infection.

Authors:  Boping Zhou; Nanshan Zhong; Yi Guan
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

3.  Transmission potential of the new influenza A(H1N1) virus and its age-specificity in Japan.

Authors:  H Nishiura; C Castillo-Chavez; M Safan; G Chowell
Journal:  Euro Surveill       Date:  2009-06-04

4.  Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009.

Authors:  Ivan F N Hung; Kelvin K W To; Cheuk-Kwong Lee; Chi-Kit Lin; Jasper F W Chan; Herman Tse; Vincent C C Cheng; Honglin Chen; Pak-Leung Ho; Cindy W S Tse; Tak-Keung Ng; Tak-Lun Que; Kwok-Hung Chan; Kwok-Yung Yuen
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic.

Authors:  Joseph T Wu; Cheuk Kwong Lee; Benjamin J Cowling; Kwok Yung Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

6.  Mitigation strategies for pandemic influenza in the United States.

Authors:  Timothy C Germann; Kai Kadau; Ira M Longini; Catherine A Macken
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  The transmissibility and control of pandemic influenza A (H1N1) virus.

Authors:  Yang Yang; Jonathan D Sugimoto; M Elizabeth Halloran; Nicole E Basta; Dennis L Chao; Laura Matrajt; Gail Potter; Eben Kenah; Ira M Longini
Journal:  Science       Date:  2009-09-10       Impact factor: 47.728

8.  Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

Authors:  Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

9.  Pandemic potential of a strain of influenza A (H1N1): early findings.

Authors:  Christophe Fraser; Christl A Donnelly; Simon Cauchemez; William P Hanage; Maria D Van Kerkhove; T Déirdre Hollingsworth; Jamie Griffin; Rebecca F Baggaley; Helen E Jenkins; Emily J Lyons; Thibaut Jombart; Wes R Hinsley; Nicholas C Grassly; Francois Balloux; Azra C Ghani; Neil M Ferguson; Andrew Rambaut; Oliver G Pybus; Hugo Lopez-Gatell; Celia M Alpuche-Aranda; Ietza Bojorquez Chapela; Ethel Palacios Zavala; Dulce Ma Espejo Guevara; Francesco Checchi; Erika Garcia; Stephane Hugonnet; Cathy Roth
Journal:  Science       Date:  2009-05-11       Impact factor: 47.728

10.  What is the optimal therapy for patients with H5N1 influenza?

Authors:  Nicholas J White; Robert G Webster; Elena A Govorkova; Timothy M Uyeki
Journal:  PLoS Med       Date:  2009-06-23       Impact factor: 11.069
View more
  2 in total

1.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 2.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.